Quest Diagnostics Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $42.8 (market cap $135.69M). The key difference: Quest Diagnostics Inc is far larger — about 187.8× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and YieldMax AI & Tech Portfolio Option Income ETF for 61 Days on average.
| DGX | GPTY | |
|---|---|---|
Market Cap | $25.48B | $135.69M |
Volume | 941,866 | 97,442 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $50.52 |
52-Week Low | $173.49 | $34.73 |
Typical Hold Time | 56 Days | 61 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →